Pakistan’s pharmaceutical industry has achieved a major milestone, recording 34% growth in exports during the fiscal year ending June 30, 2025. With total exports reaching $457 million, this marks the highest growth in two decades, positioning the sector as one of Pakistan’s fastest-growing export categories.
Compared to last year’s $341 million, this surge is the strongest since 2009. The broader category of therapeutic goods — including pharmaceuticals, surgicals, medical devices, food supplements, and nutraceuticals — also posted impressive figures, with total exports valued at $909 million, just shy of the billion-dollar mark.
The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) credited this boom to favorable government policies, especially the deregulation of non-essential medicines introduced in February 2024. This policy shift enabled companies to adjust prices, focus on exports, and invest in local production capacity while reducing black-market activities.
Industry experts say this growth not only boosts export revenue but also attracts foreign direct investment in Pakistan’s pharmaceutical sector, reinforcing a positive outlook for long-term market stability and innovation.
With the right momentum, Pakistan’s pharma industry is set to emerge as a key player in the global therapeutic goods market.
